



March 10, 2014

To Whom It May Concern



Company Name: Nichi-Iko Pharmaceutical Co., Ltd.
(Securities Code 4541 Tokyo Stock Exchange,
First Section)

Representative: Yuichi Tamura
President and CEO
Contact: Mitsuyuki Azuma
General Manager of Corporate
Planning Office
(Tel: 076-442-7026)

Notice of Decision on Name of New Company for Business Succession of Fuji Plant
between the Company and Astellas Pharma Group: Nichi-Iko Pharma Tech Co., Ltd.

As announced in the "Notice of Final Agreement on the Business Succession of Fuji Plant of Astellas Pharma Group," dated December 13, 2013, Nichi-Iko Pharmaceutical Co., Ltd. (the "Company") will succeed through company divestiture to the business of Fuji Plant (Fuji-shi, Shizuoka) of Astellas Pharma Tech Co., Ltd. (headquarters: Chuo-ku, Tokyo; President and CEO: Takashi Shimizu), a Japanese production subsidiary of the Astellas Group, effective April 1, 2014. In association with this, the Company hereby announces that the name of the new company will be Nichi-Iko Pharma Tech Co., Ltd., while the plant will be called the Shizuoka Plant.

Particulars

1. Intended new company name and overview
 - (1) New company name: Nichi-Iko Pharma Tech Co., Ltd.
 - (2) Capital: 100 million yen
 - (3) Head office: 88 Nakakawahara, Fuji-shi, Shizuoka
 - (4) Plant name: Shizuoka Plant (address same as above)
 - (5) Business year: April 1 every year to March 31 the following year
 - (6) Directors: Katsuhiko Sei
Toru Ishise
Shuukou Urayama
Nobuyuki Nagano
*Katsuhiko Sei will be the representative director, Toru Ishise will be a representative director and factory manager.
 - (7) Auditor: Shigekatsu Kumada
 - (8) Main business operations: Manufacture of pharmaceuticals
2. Date of the Business Succession
December 13, 2013 Signing of the final agreement
April 1, 2014 Completion of the business succession (scheduled)
3. Future Prospects
Though this succession will have only a minor impact on consolidated performance for the fiscal year ending March 31, 2014, it is expected to contribute to business performance from the succeeding period. Any changes occurring in the future will be made public immediately.

End